CN107735088B - 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 - Google Patents

组蛋白脱乙酰酶抑制剂及其组合物和使用方法 Download PDF

Info

Publication number
CN107735088B
CN107735088B CN201680040061.8A CN201680040061A CN107735088B CN 107735088 B CN107735088 B CN 107735088B CN 201680040061 A CN201680040061 A CN 201680040061A CN 107735088 B CN107735088 B CN 107735088B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
azabicyclo
acceptable salt
heptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680040061.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107735088A (zh
Inventor
C·多明格斯
M·C·梅拉德
A·F·豪根
A·范德波尔
A·J·斯多特
C·A·卢克赫斯特
E·A·萨维尔-斯冬斯
G·威沙特
M·沃尔
P·布莱斯亚
R·E·贾维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation Inc
Original Assignee
CHDI Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation Inc filed Critical CHDI Foundation Inc
Publication of CN107735088A publication Critical patent/CN107735088A/zh
Application granted granted Critical
Publication of CN107735088B publication Critical patent/CN107735088B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CN201680040061.8A 2015-05-07 2016-05-06 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 Active CN107735088B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
US62/158,363 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
CN107735088A CN107735088A (zh) 2018-02-23
CN107735088B true CN107735088B (zh) 2021-11-02

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040061.8A Active CN107735088B (zh) 2015-05-07 2016-05-06 组蛋白脱乙酰酶抑制剂及其组合物和使用方法

Country Status (11)

Country Link
US (2) US10053434B2 (https=)
EP (1) EP3291810B1 (https=)
JP (1) JP6805172B2 (https=)
KR (1) KR20180002729A (https=)
CN (1) CN107735088B (https=)
AU (1) AU2016258188B2 (https=)
CA (1) CA2984618C (https=)
EA (1) EA036965B1 (https=)
IL (1) IL255448B2 (https=)
MX (1) MX378983B (https=)
WO (1) WO2016179554A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180002729A (ko) * 2015-05-07 2018-01-08 씨에이치디아이 파운데이션, 인코포레이티드 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법
EA035592B1 (ru) 2015-05-07 2020-07-13 Сиэйчдиай Фаундэйшн, Инк. Ингибиторы деацетилаз гистонов и композиции и способы их применения
US10757941B2 (en) * 2016-07-22 2020-09-01 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
US20240327361A1 (en) * 2021-02-15 2024-10-03 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
CN103764635A (zh) * 2011-07-08 2014-04-30 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828171B1 (en) 2004-12-10 2014-03-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Heterocycle derivatives as histone deacetylase (hdac) inhibitors
CN103221047B (zh) 2010-01-13 2014-12-17 坦颇罗制药股份有限公司 化合物和方法
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
CA2856334A1 (en) * 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
EP3130583B1 (en) * 2012-04-05 2024-01-03 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA035592B1 (ru) 2015-05-07 2020-07-13 Сиэйчдиай Фаундэйшн, Инк. Ингибиторы деацетилаз гистонов и композиции и способы их применения
KR20180002729A (ko) * 2015-05-07 2018-01-08 씨에이치디아이 파운데이션, 인코포레이티드 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법
ES2774510T3 (es) 2015-07-27 2020-07-21 Chong Kun Dang Pharmaceutical Corp Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos
FI3328843T3 (fi) 2015-07-27 2023-01-31 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
RU2709207C2 (ru) 2015-08-04 2019-12-17 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
CN103764635A (zh) * 2011-07-08 2014-04-30 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment

Also Published As

Publication number Publication date
JP6805172B2 (ja) 2020-12-23
CA2984618C (en) 2024-01-09
AU2016258188A1 (en) 2017-11-23
US10053434B2 (en) 2018-08-21
JP2018515489A (ja) 2018-06-14
US20160326124A1 (en) 2016-11-10
IL255448B1 (en) 2023-03-01
MX378983B (es) 2025-03-10
AU2016258188B2 (en) 2021-08-26
IL255448B2 (en) 2023-07-01
EA201792247A1 (ru) 2018-06-29
EP3291810B1 (en) 2022-08-10
EP3291810A1 (en) 2018-03-14
WO2016179554A1 (en) 2016-11-10
EA036965B1 (ru) 2021-01-20
US20190202795A1 (en) 2019-07-04
CN107735088A (zh) 2018-02-23
MX2017014300A (es) 2018-08-09
EP3291810A4 (en) 2018-11-07
IL255448A0 (en) 2017-12-31
BR112017023711A2 (pt) 2018-07-17
CA2984618A1 (en) 2016-11-10
HK1252487A1 (en) 2019-05-24
KR20180002729A (ko) 2018-01-08

Similar Documents

Publication Publication Date Title
CN107735087B (zh) 组蛋白脱乙酰酶抑制剂及其组合物和使用方法
CN107735088B (zh) 组蛋白脱乙酰酶抑制剂及其组合物和使用方法
CN120077051A (zh) Kras抑制剂
US10106535B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP2968233A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
MX2013008629A (es) Inhibidores de histona desacetilasa y composiciones y metodos para su uso.
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
BR112017023711B1 (pt) Inibidores de histona deacetilase e composições e métodos de uso dos mesmos
HK1252489B (en) Histone deacetylase inhibitors and compositions and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant